Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
Döhner, Hartmut DiNardo, Courtney D Wei, Andrew H Löwenberg, Bob Appelbaum, Frederick Craddock, Charles Dombret, Hervé Ebert, Benjamin L Fenaux, Pierre Godley, Lucy A
Döhner, Hartmut
DiNardo, Courtney D
Wei, Andrew H
Löwenberg, Bob
Appelbaum, Frederick
Craddock, Charles
Dombret, Hervé
Ebert, Benjamin L
Fenaux, Pierre
Godley, Lucy A
Abstract
The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2024-08-12
Type
Article
Subject
Collections
Citation
Döhner H, DiNardo CD, Wei AH, Löwenberg B, Appelbaum F, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele GJ, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024 Aug 12:blood.2024025409.